Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKeras Res Regulatory News (KRS)

Share Price Information for Keras Res (KRS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.70
Bid: 2.60
Ask: 2.80
Change: 0.00 (0.00%)
Spread: 0.20 (7.692%)
Open: 2.95
High: 2.95
Low: 2.70
Prev. Close: 2.70
KRS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Distribution of Calidus Shares - Replacement

27 Sep 2019 10:31

RNS Number : 9580N
Keras Resources PLC
27 September 2019
 

 

The following amendment has been made to the Distribution of Calidus Shares & Proposed Capital Reduction announcement released on 27 September 2019 at 07:00 under RNS No. 8769N.

The sentence "The Demerger is considered to be a fundamental change of business pursuant to AIM Rule 15 and therefore requires the approval of Shareholders at a General Meeting to be held on 12 October 2019" incorrectly stated the date of the Company's General Meeting as 12 October 2019, rather than the correct date of 14 October 2019.

All other details remain unchanged

The full amended version is shown below.

 

 

 

Keras Resources plc / Index: AIM / Epic: KRS / Sector: Mining

27 September 2019

Keras Resources plc ('Keras' or the 'Company')

Distribution of Calidus Shares & Proposed Capital Reduction

 

Keras Resources plc, the AIM listed mineral resource company, is pleased to announce that it will today post a Circular including a notice of General Meeting to be held on 14 October 2019 detailing the proposed distribution of its 33.71% interest in ASX listed Calidus Resources Ltd ('Calidus') to the Company's Shareholders ('the Demerger'). The Circular and proxy forms are available to view and download on Keras' website. The distribution will be made through a shareholder and court approved capital reduction of the Company and a repayment to shareholders of that capital in Calidus shares ('Capital Reduction'). The Board believes that the Demerger will release significant value to shareholders and represents the most efficient way to provide shareholders with direct exposure to both Keras's and Calidus's business interests.

 

The General Meeting of the Company will be held at Craven House, West Street, Farnham, Surrey, GU9 7EN on Monday 14 October 2019 at 11.00 a.m.

 

Capitalised terms used in this announcement shall have the same meaning as set out in the Circular issued by the Company dated 27 September 2019.

 

Overview

·; Intention to demerge entire 723,750,000 shareholding of Calidus Shares held by Keras, and to distribute them to the Eligible Shareholders (currently anticipated to be those on the register at 6.00 p.m. on 19 November 2019)

·; Proposed Capital Reduction will result in the creation of distributable reserves, which is required for the Company to then effect the distribution of Calidus shares

·; The Demerger is considered to be a fundamental change of business pursuant to AIM Rule 15 and therefore requires the approval of Shareholders at a General Meeting to be held on 14 October 2019

·; Eligible Shareholders will receive 1 Calidus Share for every 3.44229 Ordinary Shares registered in their names on the Record Date

 

Recommendation

·; On 25 September 2019, the latest practicable date prior to the printing of the circular, the Calidus Shares had a total value of £11,039,927 (based on the mid-market closing price quoted on the ASX and the applicable rate of exchange between the pound and the Australian dollar), which is greater than the total market capitalisation of Keras of £10.46m at the same time.

·; The Directors believe the key advantages to the Demerger include:

o Total value for Shareholders will be materially increased by separating the interests in the two businesses

o Current deficit on distributable reserves will be eliminated, so that in future the Company will have flexibility to consider the payment of dividends and otherwise return value to its Shareholders

o Enables Keras to focus on commencing imminent production at Nayega manganese mine in Togo and implementing strategy to invest in other natural resources projects which the Board believe have early cash flow potential

·; The Directors unanimously recommend that Shareholders vote in favour of the Demerger as the Directors intend to do in respect of their own (and connected persons') beneficial shareholdings totalling 642,518,464 Ordinary Shares, representing approximately 25.79% of the Company's issued voting share capital as at the date of the Circular

·; The Directors believe Calidus has a very exciting 12 months ahead, with a fully funded large drill programme targeting mine life increase for the Definitive Feasibility Study

 

Keras Post Demerger

·; 85% interest in Societé General des Mines ('SGM'), which holds the exploration licences over the Nayega manganese project in northern Togo, with an independent JORC compliant Measured and Indicated mineral resource of 11Mt at 13.1% Mn and a Mineral Reserve of 8.5Mt at 14.0%

·; Exploitation permit awaiting Government approval with installed processing capacity to produce 6,500 tonnes per month of beneficiated manganese ore. All paperwork complete, now only awaiting the Council of Ministers Approval which requires all involved Ministers to be present at one meeting. Keras continues to actively engage with the Government of Togo to clear this final hurdle

·; Togo has had a transformational year following accreditation by Moody's Investors Service with a B3 credit rating and a single-B rating with a stable outlook from Standard & Poor, validating the Company's investment in Nayega

·; The Company continues to actively assess new projects that require low capital expenditure and have near term cashflow potential

·; Research published on Keras including a valuation on the Nayega project is available on the Company's website: https://www.kerasplc.com/company-research/

 

Russel Lamming, CEO of Keras Resources, said, "Today starts the release of approximately £11m of value to shareholders with the proposed distribution of Keras's Calidus shares and provides visibility on the potential value of both companies. The Board is pleased to participate in this distribution too and recommends that you vote in favour of the resolutions. 

 

"Post the Demerger, Keras will be transitioning from explorer to producer and, subject to the grant of an exploitation permit, it is well positioned to become a cashflow positive mining company with the flexibility to consider the payment of dividends. Although the Nayega permitting process has taken longer than expected, it is important to note that Togo has also had a transformational year following accreditation by Moody's Investors Service with a B3 credit rating and a single-B rating with a stable outlook from Standard & Poor. This puts the country of eight million people on a par with its neighbour Ghana. Recently, the Togolese Ministry of Mines awarded a large-scale exploitation permit on the Ledjoblibo clay deposit in the Kara region, approximately 200km south of Nayega. We believe that the Nayega permit is part of the Ministry's ongoing permitting schedule.

 

"Furthermore, we are focused on identifying additional value accretive projects, which offer exposure to near-term cash generation and look forward to updating shareholders on a regular basis."

 

 

CIRCULAR DETAILS

 

IMPORTANT INFORMATION

 

Forward looking statements

 

Certain statements in this Document constitute ''forward looking statements''. Forward looking statements include statements concerning the plans, objectives, goals, strategies and future operations and performance of the Company and the assumptions underlying these forward looking statements. The Company uses the words ''anticipates'', ''estimates'', ''expects'', ''believes'', ''intends'', ''plans'', ''may'', ''will'', ''should'', "could" and any similar expressions to identify forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other important factors that could cause the Company's actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future. These forward looking statements speak only as at the date of this Document. The Company expressly disclaims any obligation or undertaking to update or to revise any forward looking statements, whether as a result of new information, future events or otherwise except to the extent required by any applicable law or regulation. All subsequent written or oral forward looking statements attributable to the Company, or persons acting on behalf of the Company, are expressly qualified in their entirety by the cautionary statements contained throughout this Document. As a result of these risks, uncertainties and assumptions, a prospective investor should not place undue reliance on these forward looking statements.

 

 

 

Expected Timetable of Principal Events

 

2019

 

Publication of this Document

27 September

 

 

Latest time and date for receipt of

Forms of Proxy for the General Meeting

11.00am on 10 October

 

 

General Meeting

11.00am on 14 October

 

 

Expected date of High Court hearing to confirm the First Reduction

5 November

 

 

Expected effective date of the First Reduction

12 November

 

 

Expected date of High Court hearing to confirm the Demerger Reduction

 

19 November

Expected Record Date *

6.00pm on the Business

Day of the High Court

order for the Demerger Reduction

 

Expected effective date of Demerger Reduction

26 November

 

 

Expected date for completion of the Demerger

26 November

 

 

Expected date for the transfer of Calidus Shares to Eligible Shareholders

By 29 November

 

 

* The Record Date is expected to be on or about 19 November 2019 and the Company will notify the firm date by Regulatory Information System prior to the Demerger becoming effective.

Notes:

1) Each of the times and dates set out in the above timetable and mentioned in this Document is subject to change by the Company, in which event details of the new times and dates will be notified by an appropriate announcement to a Regulatory Information Service.

2) References to times in this Document are to London times unless otherwise stated.

3) All events in the above timetable following the holding of the General Meeting are conditional upon: (i) the passing of the Resolutions; (ii) approval of the Capital Reduction by the High Court; and (iii) registration of the High Court Order confirming the Capital Reduction with the UK Registrar of Companies.

 

 

LETTER FROM THE CHAIRMAN

 

Proposed Capital Reduction and Demerger of Calidus Shares

 

1. Introduction

 

Until June 2017, the Company carried out business as a gold producer and explorer in Australia through its wholly owned subsidiary, Keras (Gold) Australia Pty Limited. In order to develop the exploration assets, further equity capital was required, which the Board believed would be best achieved by listing on the ASX. This listing involved reversing Keras (Gold) Australia Pty Limited into an Australian shell company, which raised the required funds and relisted on the ASX as Calidus Resources Limited. The Company received both ordinary shares and performance shares in Calidus. The performance shares converted to ordinary shares in Calidus on the achievement of certain exploration milestones. Under ASX rules, all the Calidus shares were in escrow for a period of 2 years. In June 2019 the escrow period ended and in July 2019 the final conversion milestone was achieved, so that the Company now owns 723,750,000 Calidus Shares.

 

On 25 September 2019, the latest practicable date prior to the printing of this Document, the Calidus Shares had a total value of £11,039,927 (based on the mid-market closing price quoted on the ASX and the applicable rate of exchange between the pound and the Australian dollar), which is greater than the total market capitalisation of Keras of £10.46m at the same time.

 

In accordance with statements in successive annual reports of Keras and the Company's announcement on 2 July 2019, the Company today announced its intention to demerge its entire holding of Calidus Shares and to distribute them to the Eligible Shareholders by way of the Demerger.

 

The objective of the Demerger is to maximise value to Eligible Shareholders through the Demerger of the Calidus Shares, and to permit Keras to focus on operating the Nayega manganese mine in Togo. In addition, the Directors are seeking other natural resources projects, in Africa and elsewhere, which have the potential to deliver positive cash flow in the short term.

 

The Demerger is considered to be a fundamental change of business pursuant to Rule 15 of the AIM Rules and therefore requires the approval of Shareholders at the General Meeting.

 

The purpose of this Document is to set out the background to and reasons for the Capital Reduction and Demerger, explain why the Directors believe that Capital Reduction and Demerger are in the best interests of Shareholders as a whole and detail the Resolutions to be put to the Shareholders at the General Meeting to be held on 14 October 2019. The formal notice of the General Meeting is set out at the end of this Document.

 

2. Background and reasons for the Demerger

The Board considers that the best interests of Shareholders are served by arranging for them to hold their Keras shares with the core mining business separately from the Calidus Shares and believes that the total value for Shareholders will be materially increased by separating the two. To achieve this, the Directors are proposing the Demerger as set out in this Document. A secondary advantage of the Demerger is that the current deficit on distributable reserves will be eliminated, so that in future the Company will have flexibility to consider the payment of dividends and otherwise return value to its Shareholders.

For the purposes of the Act and applicable accounting standards, the Company's capital comprises its share premium account, a non- distributable capital reserve treated, except in limited circumstances, as part of the Company's paid up share capital, together with its Ordinary Shares and Deferred Shares.

In accordance with the Act, a company may, with the sanction of a special resolution and the confirmation of the Court, reduce/ cancel its share capital and share premium account. It may apply the sums resulting from such reduction, amongst other things, in either repaying holders of the relevant shares the amounts paid up on the share capital, which is reduced or cancelled or in crediting the company's profit and loss account.

On 31 August 2019, and at the date of this Document, the total capital of Keras amounted to £18,204,730 comprising a share premium account of £10,938,195, Deferred Shares of £4,775,178 and Ordinary Shares of £2,491,357. The Deferred Shares have no voting rights or value to Shareholders, and it is proposed that they be cancelled in their entirety. So far as the Ordinary Shares are concerned, it is proposed that the nominal value of each share be reduced from 0.1p per share to 0.01p per share, thus reducing the total nominal value of the Ordinary Shares in issue from £2,491,357 to £249,136. On this basis the total Capital Reduction will be £17,955,594.

At 31 August 2019, the Company had a deficit on profit and loss account of £9,676,042. As a first step to achieving the Demerger, it is necessary to eliminate this deficit by cancelling the balance standing to the credit of the Company's share premium account. This is the First Reduction.

Once the First Reduction has become effective, the Company will undertake the Demerger Reduction, pursuant to which (i) the capital paid up on each issued Deferred Share and (ii) capital in the sum of 0.09p paid up on each issued Ordinary Share will be cancelled and repaid to Eligible Shareholders. In satisfaction of the Company's obligation to repay the capital released pursuant to the Demerger Reduction, the Company will transfer Calidus Shares to Eligible Shareholders on a pro rata basis.

The Company currently has 2,491,358,439 Ordinary Shares in issue and owns 723,750,000 Calidus Shares. Pursuant to the Demerger, Eligible Shareholders will receive 1 Calidus Share for every 3.44229 Ordinary Shares registered in their names on the Record Date. Fractional entitlements will be ignored.

If the First Reduction and the Demerger Reduction are approved by the Shareholders at the General Meeting, they will be subject to the scrutiny of, and confirmation by, the High Court to ensure that the interests of existing creditors are protected and, subject to confirmation of each of the First Reduction and the Demerger Reduction; and registration by the Registrar of Companies of the order of the High Court, is the Demerger is expected to take effect on 26 November 2019. Assuming that there is no material change in the financial position or prospects of the Company, and subject to any undertakings which the Company may be required to offer the High Court for the protection of creditors, the Directors anticipate that the Capital Reduction will result in the creation of distributable reserves of approximately £2.2 million as shown in the Pro Forma Balance Sheet on page 15 of the Circular.

Calidus will continue to be listed on the ASX, and to comply with the ASX disclosure requirements including regular news releases and updates on business development and performance. These will be available on the website of Calidus at www.calidus.com.au. Calidus Shares transferred to Eligible Shareholders will be in issuer-sponsored form. Calidus' share register administers the security holder's holding and issues the investor with a security-holder reference number (SRN) which may be quoted when selling. Further information on the ASX is included in Part 2 of the Circular.

For UK tax purposes Calidus is classified as a quoted company rather than an unquoted company, as is the case with Keras.

Following the Capital Reduction, existing Keras share certificates (including share certificates issued when the Company's name was Ferrex plc) will remain valid in respect of certificated holdings in the Company. With regard to uncertificated shareholdings, the existing ISIN of GB00B649J414 will not change.

3. Capital Reduction - Procedure

In order to effect the First Reduction and the Demerger Reduction, the Company first requires the authority of its Shareholders by the passing of the Resolutions at the General Meeting.

Following the General Meeting the Company will make applications to the High Court to confirm the First Reduction and Demerger Reduction. Once the First Reduction and Demerger Reduction have been approved by the High Court and have become effective upon registration of the Court orders by the Registrar of Companies, the Company shall complete the Demerger through the distribution to the Eligible Shareholders in specie all of the Calidus Shares on the basis set out above.

The Company has provisionally scheduled the two Court hearings to effect the Capital Reduction. At the first hearing on 5 November 2019, the Company will ask the Court to confirm the First Reduction. If the Court confirms the First Reduction, the Company will deliver the Court's order to the Registrar of Companies for registration, whereupon the First Reduction will become effective. At the second Court hearing, which has been provisionally scheduled to take place on 19 November 2019, the First Reduction will have become effective, the Company will ask the Court to confirm the Demerger Reduction. If the Court confirms the Demerger Reduction, the Company will deliver the Court's order to the Registrar of Companies for registration, whereupon the Demerger Reduction will become effective. The effective date for completion of the Demerger is currently expected to be no later than 26 November 2019.

In order to approve the Capital Reduction, the High Court will need to be satisfied that the interests of the creditors of the Company will not be prejudiced. It is unlikely that any undertaking will be required to be given by the Company for the protection of creditors, given that the Company has been advised that the relatively small amount due to creditors and the value of the assets and the continuing business of the Company, reduce the likelihood that such an undertaking would be required.

The Directors reserve the right (where necessary by application to the High Court) to abandon, discontinue or adjourn any application to the High Court for confirmation of the Capital Reduction, and hence the Capital Reduction and Demerger, if the Directors believe that the terms required to obtain confirmation are unsatisfactory to the Company or if, as the result of a material unforeseen event, the Directors consider that to continue with the Capital Reduction and Demerger is inappropriate or inadvisable.

5. TaxationUnder UK tax law, the Demerger should, subject to the tax position of any particular Shareholder, result in individual UK resident taxpayers receiving their proceeds as capital for taxation purposes, although dealers in securities or persons regarded as having obtained their Ordinary Shares or Deferred Shares by reason of employment, may have a different tax treatment and should seek professional advice on their own position. For information regarding the tax position of the Demerger, please see Part 2 of this Document.

 

The Calidus Shares come within the definition of taxable Australian property for the purposes of Australian taxation. It follows that the Demerger is potentially an event which could give rise to a tax liability in Australia, so far as either the Company or the Eligible Shareholders are concerned. A draft Class Ruling ("Ruling") has been obtained from the Australian Tax Office ("ATO") confirming that the transactions set out in this document will qualify for demerger rollover relief in Australia, so that no liability for Australian tax will fall on the Company or any Eligible Shareholder who is a UK resident for tax purposes. A final Ruling will only be issued by the ATO following confirmation by the Court of the Demerger Reduction.

 

In general terms, a future sale of Calidus shares by Eligible Shareholders who are UK resident will not be subject to Australian tax provided the shareholder does not hold a 10% or greater shareholding interest in Calidus at the time.

 

If you are subject to taxation in a jurisdiction other than the UK or Australia or are in any doubt as to your tax position, you should consult an appropriate independent professional adviser.

 

6. Australian Shareholders

Australian resident shareholders will be eligible for demerger rollover relief. In accordance with the draft Ruling, the following Australian tax consequences will arise for Australian shareholders who choose demerger rollover relief for their Keras shares:

(i) Any capital gain made will be disregarded;

(ii) The cost base of Keras shares will be reduced and apportioned between Keras and Calidus shares based on their relative market values as of the Record Date;

(iii) Holders will be taken to have acquired the Calidus shares for the purpose of whether a discount capital gain is made from a future disposal of those shares on the date that the corresponding Keras shares were acquired; and

(iv) No part of the value of the Calidus shares will be treated as an assessable dividend.

 

Further details will be included in the Ruling when it is issued by the ATO.

 

7. Other Overseas Shareholders

The implications of the Demerger for Other Overseas Shareholders may be affected by the laws of the jurisdiction in which they are resident or otherwise located. Other Overseas Shareholders should inform themselves about and observe all applicable legal requirements. It is the responsibility of any person into whose possession this document comes, to satisfy themselves as to the full observance of the laws of the relevant jurisdiction in connection with the transfer of Calidus Shares pursuant to the Demerger, including the obtaining of any governmental, exchange control or other consents which may be required, and/or compliance with other necessary formalities which are required to be observed and the payment of any issue, transfer or other taxes or levies due in such jurisdiction.

8. Action to be taken

A reply-paid Form of Proxy for use in connection with the General Meeting is enclosed with this Document. Whether or not you intend to be present at the General Meeting, you are requested to complete, sign and return the Form of Proxy in accordance with the instructions printed thereon to the Company at its registrars (by post to Share Registrars Limited at The Courtyard, 17 West Street, Farnham, Surrey GU9 7DR or by scan and email to voting@shareregistrars.uk.com) as soon as possible and, in any event, not later than 11.00 a.m. on 10 October 2019, being 48 hours (excluding non-business days) before the time of the General Meeting. The completion and return of the Form of Proxy will not preclude you from attending the General Meeting and voting in person should you subsequently wish to do so.

The Demerger can only be implemented if the Resolutions are approved by the requisite majority at the General Meeting and the Capital Reduction is confirmed by the High Court. It is therefore important that you either vote in person or by proxy at the General Meeting.

Shareholders are reminded that, if their Ordinary Shares are held in the name of a nominee, only that nominee or its duly appointed proxy can be counted in the quorum at the General Meeting.

9. Recommendation

The Directors consider that the proposals and the passing of the Resolutions to be proposed at the General Meeting is in the best interests of the Company and its Shareholders as a whole. Accordingly, your Directors unanimously recommend that you vote in favour of the Resolutions set out in the notice of General Meeting as the Directors intend to do in respect of their own (and connected persons') beneficial shareholdings totalling 642,518,464 Ordinary Shares, representing approximately 25.79% of the Company's issued voting share capital as at the date of this Document.

Whether or not you are able to attend the General Meeting in person, please read the notice of General Meeting set out at the end of this Document and the enclosed Form of Proxy, including the notes thereto carefully, to ensure you are able to record your votes in respect of the Resolutions to be proposed at the General Meeting.

Yours sincerely

Brian Moritz

Non-Executive Chairman

 

THE AUSTRALIAN SECURITIES EXCHANGE

 

The Australian Securities Exchange (ASX) is Australia's primary securities exchange. It is owned by the Australian Securities Exchange Ltd, an Australian public company. Prior to December 2006 it was known as the Australian Stock Exchange, which was formed on 1 April 1987, incorporated under legislation of the Australian Parliament as an amalgamation of the six state securities exchanges.

 

Currently, ASX has an average daily turnover of approx. A$4.685 billion (£2.6 billion) and a market capitalisation of approx. A$1.9 trillion (£1.06 trillion), making it one of the world's top 16 listed exchange groups.

 

ASX is a market operator, clearing house and payments system facilitator. It also oversees compliance with its operating rules, promotes standards of corporate governance among Australia's listed companies and helps to educate retail investors.

 

All ASX equity securities are traded on screen on ASX Trade. ASX Trade is a NASDAQ OMX ultra-low latency trading platform based on NASDAQ OMX's Genium INET system, which is used by many exchanges around the world. It is one of the fastest and most functional multi-asset trading platforms in the world, delivering latency down to ~250 microseconds.

 

Security holders hold shares in one of two forms, both of which operate as uncertificated holdings, rather than through the issue of physical share certificates:

1. Clearing House Electronic Sub-Register System (CHESS). The investor's controlling participant (normally a broker) sponsors the client into CHESS. The security holder is given a "holder identification number" (HIN) and monthly statements are sent to the security holder from the CHESS system when there is a movement in their holding that month.

2. Issuer-sponsored. The company's share register administers the security holder's holding and issues the investor with a security-holder reference number (SRN) which may be quoted when trading in Calidus securities.

 

Holdings may be moved from issuer-sponsored to CHESS or between different brokers by electronic message initiated by the controlling participant.

 

Many British-based stockbrokers can buy and sell shares listed on ASX, and may produce contract notes in sterling or in Australian dollars. Because of the time difference, deals are typically processed when the ASX next opens. Alternatively, holders of Calidus Shares resident in the UK are able to open an account with an Australian stockbroker.

 

 

TAXATION

 

The following comments are intended as a general guide only and are based on current UK legislation and Her Majesty's Revenue and Customs practice as at the date of this Document. These comments deal only with Shareholders who are resident for taxation purposes in the United Kingdom, who are the absolute beneficial owners of fully paid Ordinary Shares and Deferred Shares and who hold such shares as an investment. These comments do not deal with other classes of Shareholders, including dealers in securities or persons regarded as having obtained their Ordinary Shares or Deferred Shares by reason of employment. Therefore, such shareholders are advised to satisfy themselves as to the tax consequences for them of their ownership of the Ordinary Shares or Deferred Shares in the Company.

 

Subject to the comments below, the Company expects the Return of Capital to be classified as a repayment of capital on the Ordinary Shares under section 1000(1)(B)(a) CTA 2010 and therefore would not expect any part of the proceeds received by a Shareholder on the Return of Capital to be an income distribution in the Shareholders hands.

 

Part 15 CTA 2010 and Chapter 1 ITA 2007 contain anti-avoidance provisions which may apply to the Return of Capital so as to treat all or part of the proceeds as income, rather than capital, in the hands of the Shareholders. Whilst these rules contain a number of subjective tests, the Company does not expect either Part 15 CTA 2010 or Chapter 1 ITA 2007 to apply to the Return of Capital.

 

On the basis of the above, the Company expects the Return of Capital to be treated as a deemed part disposal of the Ordinary Shares for Shareholders under section 122 TCGA 1992 which may give rise to a liability for Shareholders to either capital gains tax or corporation tax depending on the Shareholder's individual circumstances (including the availability of exemptions, reliefs of allowable losses). Please see example below.

 

In accordance with section 748 of the Corporation Tax Act 2010 and section 701 of the Income Tax Act 2007, the Company has applied for clearance from HM Revenue & Customs that they are satisfied that the transactions in securities provisions should not be applied to the proposal.

Example

Please note, that the example below is for illustrative purposes only.

 

The Demerger will be treated as a part disposal by Shareholders and the tax treatment will vary depending on individual circumstances. As only part of the investment in Keras has been returned, only part of the cost of that investment can be deducted in the tax computation of the gain or loss accruing on the part disposal.

 

The allowable investment expenditure is apportioned using the formula A / (A + B) x C, where:

A = the value of the Calidus Shares received

B = the market value of the shareholding in Keras after the Demerger

C = the original cost of Ordinary Shares

·; Shareholder owns 3,200,000 Ordinary Shares 

·; Original cost of investment is £20,000 (C)

·; Capital returned is 1,000,000 Calidus Shares at $0.03 per share ($30,000 = £16,949) (A)

·; The exchange rate at date of distribution is GBP/AUD 1.77

·; The value of the Keras shareholding after capital distribution is £6,400 (B)

The cost apportioned to the disposal is (20,000 x 16,949/ (16,949+6400)) = £14,518

The gain on Demerger is

Capital returned

16,949

Less: allowable cost of investment

14,518

Gain on Return of Capital

2,431

 

As the gain of £2,431 is below the personal capital gains tax allowance for 2019/20 of £12,000 (assuming no other transactions) no capital gains tax would be payable.

 

The value of each Calidus Share received (as in A above) will be as at the date of the distribution and the market value of a share in Keras will be the open market value after the Demerger (as in B above) and will be prominently displayed on the Keras website - www.kerasplc.com - on completion of the Demerger.

 

Please note that the Company is not able to provide tax advice and this example is for illustrative purposes only. You should accordingly seek appropriate guidance or advice when completing any tax return which reflects any matters for which the apportionment is relevant.

 

FINANCIAL INFORMATION

UNAUDITED BALANCE SHEET OF KERAS AT 31 AUGUST 2019

 

 

 

 

 

 

 

 

 

 

 

 

Unaudited

31 August 2019

£'000

Audited

30 Sept. 2018

£'000

 

Assets

 

 

 

 

 

 

 

 

 

Property, plant and equipment

 

 

 

 

 

 

316

230

 

Other investments

 

 

 

 

 

 

-

-

 

Non-current assets

 

 

 

 

 

 

316

230

 

 

 

 

 

 

 

 

 

 

 

Financial assets at fair value

 

 

 

 

 

 

12,024

11,527

 

Loans to subsidiaries

 

 

 

 

 

 

1,756

1,484

 

Trade and other receivables

Unpaid share capital

 

 

 

 

 

 

17

323

15

-

 

Cash and cash equivalents

 

 

 

 

 

 

10

208

 

Current assets

 

 

 

 

 

 

14,130

13,234

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

 

 

 

 

14,446

13,464

 

 

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

Share capital

 

 

 

 

 

 

7,267

7,064

 

Share premium

Assets for sale reserve

 

 

 

 

 

 

10,938

5,559

10,358

5,063

 

Other reserves

 

 

 

 

 

 

150

108

 

Retained deficit

 

 

 

 

 

 

(9,676)

(9,876)

 

Total equity attributable to owners of the Company

 

 

14,238

12,717

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

Trade and other payables

Accruals

 

 

 

 

 

 

57

151

707

40

 

Current liabilities

 

 

 

 

 

 

208

747

 

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

 

 

 

 

208

747

 

 

 

 

 

 

 

 

 

 

 

Total equity and liabilities

 

 

 

 

 

 

14,446

13,464

 

 

 

PRO-FORMA BALANCE SHEET OF KERAS

 

The pro-forma Balance Sheet of Keras set out below is based on the unaudited Balance Sheet at 31 August 2019 adjusted for the effect of the Resolutions to be proposed at the General Meeting, comprising:

 

1. The First Reduction; and

2. The Demerger Reduction

 

 

 

 

 

 

 

 

 

 

 

Unaudited

31 August 2019

£'000

First

Reduction

 

£'000

Demerger

Reduction

 

£'000

Pro-forma

 

£'000

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Property, plant and equipment

 

 

 

 

 

 

316

 

 

316

 

Other investments

 

 

 

 

 

 

-

 

 

-

 

Non-current assets

 

 

 

 

 

 

316

 

 

316

 

 

 

 

 

 

 

 

 

 

 

 

 

Financial assets at fair value

 

 

 

 

 

 

12,024

 

(12,024)

-

 

Loans to subsidiaries

 

 

 

 

 

 

1,756

 

 

1,756

 

Trade and other receivables

Unpaid share capital

 

 

 

 

 

 

17

323

 

 

16

323

 

Cash and cash equivalents

 

 

 

 

 

 

10

 

 

11

 

Current assets

 

 

 

 

 

 

14,130

 

(12,024)

2,106

 

 

 

 

 

 

 

 

 

 

 

 

 

Total assets

 

 

 

 

 

 

14,446

 

(12,024)

2,422

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

Share capital

 

 

 

 

 

 

7,267

 

(7,018)

249

 

Share premium

 

 

 

 

 

 

10,938

(10,938)

 

-

 

Assets for sale reserve

 

 

 

 

 

 

5,559

 

(5,559)

-

 

Other reserves

 

 

 

 

 

 

150

 

 

150

 

Retained deficit

 

 

 

 

 

 

(9,676)

10,938

553

1,815

 

Total equity attributable to owners of the Company

14,238

-

(12,024)

2,214

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

Trade and other payables

Accruals

 

 

 

 

 

 

57

151

 

 

57

151

 

Current liabilities

 

 

 

 

 

 

208

 

 

208

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

 

 

 

 

208

 

 

208

 

 

 

 

 

 

 

 

 

 

 

 

 

Total equity and liabilities

 

 

 

 

 

 

14,446

 

 

2,422

 

 

 

 

DEFINITIONS

Act

the Companies Act 2006

 

AIM

the market of that name operated by the London Stock Exchange Plc

 

AIM Rules

the AIM Rules for Companies

 

ASX

Australian Securities Exchange Limited

ATO

Australian Taxation Office

 

Board

the board of directors of the Company from time to time

 

Calidus

Calidus Resources Limited

 

Calidus Shares

the 723,750,000 ordinary shares in Calidus held by the Company

 

Capital Reduction

the proposed reduction of the Company's capital by way of the First Reduction and the Demerger Reduction, as described in this Document

 

Company or Keras

Keras Resources Plc

 

CREST

the computerised settlement system (as defined in the CREST Regulations) operated by Euroclear UK & Ireland Limited which facilitates the transfer of title to shares in uncertificated form

 

Deferred Shares

the deferred shares of 0.4p each in the capital of the Company

 

Demerger

the demerger of all of the Calidus Shares to the Eligible Shareholders on a pro rata basis in satisfaction of the Company's obligation to repay the capital released pursuant to the Demerger Reduction as described in this Document

 

Demerger Reduction

 

the cancellation of: (i) capital in the sum of 0.09p paid up on each issued Ordinary Share and (ii) the capital paid upon on each issued Deferred Share

 

Directors

the directors of the Company as at the date of this Document whose names are set out on page 5 of this Document

 

Document or Circular

this document, being a circular to Shareholders and the accompanying notice of General Meeting dated 27 September 2019

 

Eligible Shareholders

the holders of the Ordinary Shares as at the Record Date

 

First Reduction

 

the cancellation of the Company's share premium account to eliminate the deficit on the Company's profit and loss account

 

Form of Proxy

the form or forms of proxy accompanying this Document relating to the General Meeting

 

General Meeting or GM

the general meeting of the Company, convened by the notice set out on page 19 of this Document, to be held at 11.00a.m. at Craven House, West Street, Farnham, Surrey, GU9 7EN, on 14 October 2019, or any adjournment of that meeting, which is being held to consider the Resolutions

 

Keras or the Company

Keras Resources Plc, a company incorporated and registered in England and Wales under company number 07353748

 

New Ordinary Shares

 

following the Demerger Reduction ordinary shares of 0.01p each in the capital of the Company

 

Ordinary Shares

the ordinary shares of 0.1p each in the capital of the Company

 

Other Overseas Shareholders

 

those Eligible Shareholders with registered addresses outside the UK or Australia who are incorporated in, registered in or otherwise resident or located in, countries outside the UK or Australia

 

Record Date

6.00pm on the Business Day of the High Court

order for the Demerger Reduction

 

Regulatory Information Service

any of the services authorised from time to time by the UK Financial Conduct Authority for the purposes of disseminating regulatory announcements

 

Resolutions

the resolutions set out in the notice of General Meeting

 

 

 

 

 

Shareholders

holders of Ordinary Shares or New Ordinary Shares (as applicable) from time to time

 

 

 

 

 

For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is being made on behalf of Russell Lamming, Chief Executive Officer. This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

**ENDS**

 

For further information please visit www.kerasplc.com, follow us on Twitter @kerasplc or contact:

 

Russell Lamming

Keras Resources plc

info@kerasplc.com

Nominated Adviser / Broker

Ewan Leggat / Charlie Bouverat

SP Angel Corporate Finance LLP

+44 (0) 20 3470 0470

 

Financial PR

Isabel de Salis / Cosima Akerman

St Brides Partners Ltd

+44 (0) 20 7236 1177

 

Notes

Keras Resources plc is focused on building a strategic portfolio of resource assets. The Company provides investors with exposure to the near-production Nayega manganese mine ('Nayega') and the Kamino, cobalt and nickel project in Togo, West Africa. It also has a significant interest in Calidus Resources Limited, a highly prospective gold exploration and development company in Australia, which completed a Pre-Feasibility Study at its Warrawoona gold project in July 2019. Keras benefits from a supportive Board of Directors currently owning 25.8% of the Company and a highly skilled management team, which has extensive operational experience in Africa and Australia and proven success in advancing assets up the value curve.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSELSUWFUSEEU
Date   Source Headline
29th Feb 20247:00 amRNSTotal Voting Rights
23rd Feb 20247:00 amRNSOperations Update and award of Options
2nd Feb 20247:00 amRNSIssue of Fee Shares
22nd Jan 20247:00 amRNSGranulator Plant JV and Acquisition of Property
17th Jan 20247:00 amRNSChange of Auditor
22nd Nov 20237:00 amRNSHolding(s) in Company
3rd Oct 202311:52 amRNSHolding(s) in Company
29th Sep 20237:00 amRNSInterim Results
4th Sep 20231:58 pmRNSHolding(s) in Company
16th Aug 20232:04 pmRNSHolding(s) in Company
1st Aug 202310:41 amRNSResult of AGM
6th Jul 20234:20 pmRNSRestoration of Trading on AIM
6th Jul 20234:20 pmRNSRestoration - Keras Resources plc
6th Jul 20237:00 amRNSFinal Results for the Year Ended 31 December 2022
5th Jul 20235:45 pmRNSHolding(s) in Company
4th Jul 20234:55 pmRNSReceipt of funds from the Republic of Togo
3rd Jul 20237:30 amRNSSuspension - Keras Resources plc
3rd Jul 20237:00 amRNSAnnual Results Update & Suspension
30th Jun 20237:05 amRNSHolding(s) in Company
30th Jun 20237:00 amRNSHolding(s) in Company
18th May 20237:00 amRNSNayéga Agreement & Strategic Update
17th Apr 20234:30 pmRNSHolding(s) in Company
17th Apr 20234:30 pmRNSTR-1: Notification of major holdings
15th Mar 20234:24 pmRNSHolding(s) in Company
20th Oct 20227:00 amRNSExtended mining campaign completed, Diamond Creek
28th Sep 20227:00 amRNSInterim Results
13th Sep 20227:00 amRNSNew Website & Presentation incl. Forecast & Event
7th Sep 20227:00 amRNSMining campaign extended due to increased demand
1st Sep 20227:00 amRNSDirectorate Changes
11th Aug 20227:00 amRNSShareholder/Investor Meeting and Presentation
4th Aug 20227:00 amRNSOperations Update - Diamond Creek Phosphate
25th Jul 202211:30 amRNSResult of AGM, Result of GM & Share Consolidation
19th Jul 202212:30 pmRNSUpdate regarding Investor Presentation and GM
15th Jul 20227:15 amRNSIssue of Equity
30th Jun 20227:00 amRNSNotice of GM and proposed Share Consolidation
30th Jun 20227:00 amRNSPosting of Annual Report and Notice of AGM
30th Jun 20227:00 amRNSFinal Results
22nd Jun 20223:20 pmRNSNew Date - Shareholder/Investor Presentation
9th Jun 20227:00 amRNSShareholder/Investor Meeting and Presentation
23rd May 20227:00 amRNSNotice of Interest in Shares
17th May 20227:03 amRNSIssue of new shares
16th May 20221:48 pmRNSResult of General Meeting
4th May 20226:23 pmRNSPosting of Circular and Notice of General Meeting
29th Apr 20221:54 pmRNSOversubscribed Broker Option Placing
26th Apr 20227:00 amRNSPlacing and Corporate Update
19th Apr 20222:48 pmRNSDirector & PCA Dealings
12th Apr 20227:00 amRNSOperational Update
6th Apr 20224:36 pmRNSPrice Monitoring Extension
5th Apr 20223:58 pmRNSHolding(s) in Company
30th Mar 20228:53 amRNSIncrease in Diamond Creek Ownership to 100%

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.